Background: Detailed polysomnography (PSG) and overnight continuous positive airway pressure (CPAP) titration as the basis for investigation and treatment of obstructive sleep apnoea/hypopnoea syndrome (OSAHS) incurs high costs from inpatient stays and technician attendance, even when split night studies are employed. Responding to rapidly increasing demand, from 1996 the sleep service at Glasgow Royal Infirmary adopted limited sleep studies and daycase CPAP titration as first line management. Here we describe the outcomes of this service between 1996 and 1999. Methods: Data were collected from prospective records made at follow up by sleep technicians and by casenote review. Results: Results were available for 158 subjects (97.5%) of 162 commenced on CPAP during this period. One hundred and forty-eight (91 %) were diagnosed by limited sleep studies and 80 (50%) were diagnosed at home. The median follow up was 23 months (interquartile range (IQR), 13-35). Median use of CPAP in those continuing therapy was 5.3 hours/night (IQR, 3.1 to 6.5) and 77% were still using CPAP at three years. Only initial low CPAP compliance (< 2 hours/night) significantly predicted early CPAP cessation. In those still on CPAP in 1999, the mean drop in Epworth Sleepiness Scale score was 4.6 points (95% confidence intervals, 3.2 to 6.0). Conclusion: These data from the CPAP population at Glasgow Royal Infirmary provide information on longterm outcomes using a diagnostic protocol based on limited sleep studies and daycase CPAP titration. Chronic
Introduction
Obstructive sleep apnoea/hypopnoea syndrome (OSAHS) is a common medical condition, which is estimated to affect up to 5% of adult men.' Given trends to increased obesity in the developed world, this prevalence is likely to increase. Whilst overnight polysonmngrahy (PSGo and orenight continuous posi*ive airway pressure (CPAP) titration were pivotal in the original approach to diagnosing the condition and prescription of treatment, limited sleep studies combined with daycase CPAP titration are more economical in terms of time and money.2
Correspondence: Dr MK Johnson, 357 Albert Drive, Glasgow G41 5PH, UK E-mail: johnson7@which.net The Glasgow Royal Infirmary sleep service was established in 1991 utilizing existing resources within a tertiary referral respiratory physiology laboratory. In common with all UK centres, we experienced a rapid increase in referral pressure from the mid-1990s onwards. Although lacking definitive evidence, a decision was taken (SWB/RC) to adopt limited sleep studies and dayc-ase CPAP tftration folilowied by homie trial and outpatient contact as a routine. The service has been running in this form since 1996 and during this time data on patient compliance and complications of CPAP therapy have been prospectively recorded by the sleep technicians.
The data presented in this study address long term outcomes from this 'first generation' of restricted sleep service.
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Methods
Structure of sleep service
At Glasgow Royal Infirmary, the sleep service is organized so as to minimize costs per patient. This is achieved by the predominant use of limited sleep studies performed at home (patient directed) or hospital (ward nurse directed) and with initial CPAP titration almost exclusively performed during office hours. The management strategy of the Sleep Service at Glasgow Royal Infirmary between 1996 and 1999 is summarized in Figure 1 . After the first clinic visit, if OSAHS were suspected or required to be excluded, then the first line investigation was a limited sleep study. This could be one of the following: The study of choice was fiveor two-channel, with oximetry restricted to high probability cases. Full polysomnography (using the SensorMedics SomnoTrac 4250 or Jaeger Sleeplab 1000P) was reserved for cases where other diagnoses such as narcolepsy were considered or as a second line investigation to address discordance between clinical findings and limited sleep study results.
The absolute indication for a trial of CPAP was an apnoea hypopnoea index (AHI) greater than 30 events/ hour (without excessive daytime somnolence) or greater than 15 events/hour (with excessive daytime somnolence). Diprate (where a dip was an oxygen desaturation >4%) was used instead of AHI when oximetry alone was recorded. Some subjects with results outside these limits were given a trial of CPAP in the presence of severe symptoms or if they were drivers by occupation or had increased cardiovascular risk (proven hypertension or ischaemic heart disease). CPAP initiation was performed in a dedicated sleep room attached to the respiratory function laboratory. The patient attended for a half day to undergo familiarization with the principles of CPAP and to size appropriate mask and headgear. The patient was then observed via video link whilst dozing with CPAP in operation. The CPAP level was selected and adjusted by experienced technicians aiming to improve diprate and breathing pattern matched to patient tolerance.
The patient was then given a CPAP machine to take away for a trial lasting a minimum of two weeks after which progress was reviewed by the sleep technicians. Trials were extended if initial difficulties were encountered. Compliance was assessed by the reading on the machine hour meter and any teething problems with headgear or machine were addressed. If the patient wished to continue after the trial period, a dedicated CPAP machine was issued. Further follow up was arranged for six months although the sleep technicians were available for consultation by telephone or in person during working hours. Replacement of equipment such as tubing or masks was usually achieved by post. At follow up visits, records were taken ofpatient compliance and problems with CPAP use. If progress was satisfactory, follow-up was changed to an annual visit.
Data collected
All patients issued with a dedicated CPAP machine at Glasgow Royal Infirmary for treatment of OSAHS between January 1996 and October 1999 were included in the study. Data were collected from both hospital case notes and from records made prospectively by sleep technicians at follow-up visits. The data consisted of patient baseline characteristics, details of sleep investigations and CPAP therapy, compliance, complications and subjective efficacy [measured by the Epworth Sleepiness Scale (ESS)]. The baseline characteristics noted were age, sex, body mass index (BMI) and the presence of a pre-existing diagnosis of hypertension or vascular disease. The details of sleep investigations included type and location of diagnostic study and the apnoea hypopnoea index (AHI) measured at that time. The information on CPAP therapy consisted of pressure setting, compliance, mask type and size, machine type and any subsequent changes of pressure level or equipment. Complications or problems with CPAP therapy were taken as those recorded by the technicians at follow up visits. All the patients in the study still on CPAP were sent a further ESS questionnaire at the time of data collection to provide follow up data on subjective efficacy.
Statistical analysis
All figures quoted are median and interquartile range (IQR) unless otherwise specified. Kaplan-Meier survival analysis was used to examine the proportion of patients continuing on CPAP. Values of ESS score pre and post CPAP therapy were compared with a paired t-test. The logrank test was used to examine for predictors of continued CPAP usage. All statistical analyses were done using the Statview program (SAS Institute Inc.). Ethical approval for the study protocol was obtained from the local ethics committee.
Results
Between 1996 and 1999, 1527 sleep studies were performed by our department. Of these, 1405 (92%) were limited studies and 974 (64%) were performed at home. One hundred and sixty-two patients were commenced on CPAP during this period. Notes were available for 158 (98%) and, of the patients where notes could not be traced, two were still on CPAP, one had switched to noninvasive ventilation (NIV) and one had stopped CPAP. In total, 14 (9%) had had PSG and 148 (91%) patients had had limited studies (96 had five channel studies, 49 had two channel studies and three had pulse oximetry) of which 80 had been performed at home.
The baseline characteristics and results of the diagnostic sleep studies from this CPAP population are shown in Table 1 . Details of CPAP therapy are summarized in Table 2 . Data on patient use of CPAP were available for 148 patients. Of the 14 with no data, nine were still on CPAP. Of the remaining five, one had CPAP withdrawn, three had died and one had moved away. After the initial equipment and treatment pressure were established, 14 patients required a change in CPAP machine, 22 needed a different mask and 26 required an adjustment of CPAP level.
The median follow-up of the patients was one year and eleven months, which gave a total of 284 patient CPAP years of data. The median (IQR) use of CPAP in all patients measured from the machine hour meter was 4.4 (2.1-6.4) hours/night. For only those patients continuing on CPAP, median (IQR) use was 5.3 (3.1-6.5) hours/night. Complications documented to have resulted from CPAP therapy are shown in Figure 2 . The proportion of patients continuing with CPAP therapy is shown as a Kaplan-Meier plot in Figure 3 . It can be seen from this plot that 87% are still on CPAP at one year and 77% at three years. Twenty-five of the patients continuing CPAP long term had a recorded use less than two hours/night. If these were considered as effectively no longer using CPAP, then the three year figure drops to 62%.
The variables assessed as predictors of continued CPAP usage are shown in Table 3 , together with the P-values generated by the logrank test. CPAP usage less than two hours/night was the only characteristic significantly associated with increased likelihood of cessation of CPAP therapy. A BMI less than 30 kg/mi2, an AHI less than 30 or 15 events per hour and diagnosis by polysomnography were associated with increased likelihood of cessation of CPAP only at a P = 0.1 level of significance. The mean + SD ESS score prior to treatment was 13.4 + 5.4 (n = 134). The ESS questionnaire was sent to the 130 patients still using CPAP and 111 patients replied (85%). The mean + SD ESS score of the respondents was 8.9 + 5.2 (n = 111). Paired ESS values before and after CPAP treatment were available for 94 patients. The mean + SD drop was 4.6 + 6.9 points (95% CI 3.2 to 6.0). 
Discussion
PSG is widely accepted as the gold standard for the diagnosis of OSAHS and it has been claimed to be the best predictor of the improvement in symptoms following the introduction of CPAP.3 However, in many cases PSG collects more information than is required to diagnose OSAHS.4 Similarly CPAP titration to choose the lowest effective treatment pressure is often done as an overnight study either at the same or a different sitting. There is little evidence as to how precisely the treatment pressure should be chosen. Whilst one study showed lower pressure resulting in greater compliance,5 others have demonstrated the converse6-8 and higher treatment pressure appears to be associated with a greater reduction in hypersomnolence.6
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The CPAP population at Glasgow Royal Infirmary were investigated and treated using an approach aimed at minimizing costs per patient. Ninety one percent of this population had limited sleep studies at diagnosis and 55% of these were performed at home. Limited studies are well suited to self initiation (supported by expert instruction and written protocol), are simpler to set up, quicker to analyse and a fraction of the cost. 2 CPAP initiation was exclusively commenced during a half day visit in office hours, with treatment pressure being selected by experienced sleep technicians. Patients started with a median CPAP level of 12 cmH2O which is high compared with other CPAP populations (cf, 8 cmH2O in Edinburgh6). This reflects our practice whereby 12 cmH2O was used as the initial treatment pressure in 122 of our patients. Subsequent adjustments of the pressure were required in only 26 individuals.
Compliance figures generated by serial readings of the hour meter on the CPAP machine have been given in several studies6'7'9-1 but they are recognized to be an overestimate. On average, the number of hours that the CPAP mask is on the face delivering an adequate pressure is approximately nine tenths of the time that the machine is running. 12 The compliance of our entire population had a median value of 4.4 hours/night (IQR 2.1-6.4) and a mean value of 4.3 hours/night (95% CI 3.8 to 4.7). If only those continuing on CPAP are included, the figures are 5.3 hours/night (3.1-6.5) and 4.8 hours/night (95% CI 4.4 to 5.2) respectively. These are well within the range of values given in previous studies of compliance, (3.2-5.8 hours/ night) 6,7,9-,3-Using Kaplan-Meier analysis, we found that 77% of our patients continued on CPAP at three years which is also within the range described elsewhere.67'6 Finally, the reduction in ESS by 4.6 points (95% CI 3.2 to 6.0) for those patients who continued with CPAP is comparable to the response to CPAP reported in severe OSAHS17 and larger than the size of effect seen due to oral placebo or sham CPAP.18 '19 Previous studies of the frequency of complications or side effects with CPAP have used devices such as self-completed questionnaires.14'20 By contrast, we have used the records of the sleep technicians taken at outpatient review. As a consequence our figures reflect those problems which required technician intervention, and the frequencies are smaller than those seen elsewhere. One hundred and twenty two (75%) of the patients reported at least one problem.
We recognize that this report taken from routine day to day sleep service records has several limitations and clearly does not fulfil the disciplines of a formal trial design. Although ascertainment of our data was not complete it is unlikely that this introduced bias as the absent data were not clustered in one group, such as those who had had CPAP withdrawn because of poor compliance. Another potential criticism is that formal sleep study confirnation of CPAP response was limited to 'problem' cases. Despite such points, it is encouraging that the results are in line with those from a major research centre (Edinburgh),6 where the system is based on PSG assessment and hospital based CPAP titration. In common with them we found that poor initial CPAP use was the strongest predictor of CPAP cessation. Other factors from the Edinburgh study such as lower BMI and lower AHI just failed to reach significance (0.1 > P > 0.05) as predictors of CPAP cessation in our study.
Whilst the data indicate that our approach delivered effective therapy to the selected patients, it is possible that some cases would have been overlooked by this approach. As patients with an elevated ESS score were not routinely discharged without further assessment or a CPAP trial, we think that such an event would be rare. From 2000 we have introduced newer options such as CPAP autotitration devices. Our impression is that median CPAP pressure is now lower, possibly suggesting a tendency to overestimate pressure requirement during the 1996 to 1999 period.
Conclusions
These data from the CPAP population at Glasgow Royal Infirmary provide information on long term outcomes following a diagnosis of OSAHS made from limited sleep studies and daycase CPAP titration. Both compliance in hours/night and proportion continuing CPAP long term are comparable with outcomes following overnight PSG and overnight CPAP titration. The improvement in sleepiness in our population is similar to that found in a meta-analysis of the studies of effectiveness. Therefore, given the pressures to provide an effective clinical service for OSAHS patients with scarce resources, we consider that these findings provide sufficient justification for further development and implementation of this model of service delivery.
